Avedro acquires assests from IROC Innocross AG

Article

Avedro Inc. recently announced that it has purchased the assets of IROC Innocross AG, of Zug, Switzerland.

Boston-Avedro Inc. recently announced that it has purchased the assets of IROC Innocross AG, of Zug, Switzerland.

FDA seeking more info on Avedro’s corneal cross-linking NDA

IROC Innocross was the first company to commercialize a cross-linking device for the treatment of keratoconus and other corneal pathologies.

With this acquisition, Avedro’s platform of cross-linking technology now covers the entire spectrum of corneal cross-linking procedures, from treating corneal pathology with our UV-X devices and MedioCROSS riboflavin–to enhancing LASIK outcomes with our KXL System andVibeX riboflavin–to developing non-invasive refractive procedures with our advanced KXL II System.

Avedro will continue to work with key IROC Innocross suppliers MDP Solutions in Switzerland and Solnovis in Germany to ensure product supply and development.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.